ReviewF1000Research2016
Geroscience approaches to increase healthspan and slow aging.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interventions that prolong multidimensional healthspan in humans: a systematic review of randomized controlled trials.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Pooled it
- Dietary pyrroloquinoline quinone and spermidine in healthy longevity: targeting the hallmarks of aging.Frontiers in aging · 2026Review
- Cyrene: a novel geroprotective compound that extends lifespan and healthspan in C. elegans and Drosophila.npj aging · 2025Article
- The efferocytosis process in aging: Supporting evidence, mechanisms, and therapeutic prospects for age-related diseases.Journal of advanced research · 2025Review
- Rejuvenating effects of young extracellular vesicles in aged rats and in cellular models of human senescence.Scientific reports · 2023Article
- Growing older with HIV in the Treat-All Era.Journal of the International AIDS Society · 2022Article
- Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery Platform.Frontiers in aging neuroscience · 2022Article
- Article
- Senolytics: targeting senescent cells for age-associated diseases.Current molecular biology reports · 2020Article
- The longevity-promoting factor, TCER-1, widely represses stress resistance and innate immunity.Nature communications · 2019Article
- Elixir of Life: Thwarting Aging With Regenerative Reprogramming.Circulation research · 2018Review
- Role of gut microbiota in aging-related health decline: insights from invertebrate models.Cellular and molecular life sciences : CMLS · 2018Review
- Extended Twilight among Isogenic C. elegans Causes a Disproportionate Scaling between Lifespan and Health.Cell systems · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
For decades, researchers in the biology of aging have focused on defining mechanisms that modulate aging by primarily studying a single metric, sometimes described as the "gold standard" lifespan. Increasingly, geroscience research is turning towards defining functional domains of aging such as the cardiovascular system, skeletal integrity, and metabolic health as being a more direct route to understand why tissues decline in function with age. Each model used in aging research has strengths and weaknesses, yet we know surprisingly little about how critical tissues decline in health with increasing age. Here I discuss popular model systems used in geroscience research and their utility as possible tools in preclinical studies in aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.